CR20150477A - Polipéptidos de il-22 y proteínas de fusión de il-22 fc y métodos de uso - Google Patents

Polipéptidos de il-22 y proteínas de fusión de il-22 fc y métodos de uso

Info

Publication number
CR20150477A
CR20150477A CR20150477A CR20150477A CR20150477A CR 20150477 A CR20150477 A CR 20150477A CR 20150477 A CR20150477 A CR 20150477A CR 20150477 A CR20150477 A CR 20150477A CR 20150477 A CR20150477 A CR 20150477A
Authority
CR
Costa Rica
Prior art keywords
methods
polypeptides
fusion proteins
composition
relates
Prior art date
Application number
CR20150477A
Other languages
English (en)
Inventor
Justin Scheer
Wenjun Ouyang
Eric Gary Stefanich
Richard Vandlen
Philip E Haas
Ganesh A Kolumam
Xiaoting Wang
Jed Ross
Bruggen Nicholas Van
Wyne P Lee
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2014/029652 external-priority patent/WO2014145016A2/en
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CR20150477A publication Critical patent/CR20150477A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a polipéptidos de IL-22, proteínas de fusión de IL-22, composición que los comprende, métodos de fabricación y métodos de utilización de la composición para el tratamiento de enfermedades. La invención también se refiere al receptor de IL-22 asociado a reactivos y métodos de uso de los mismos.
CR20150477A 2013-03-15 2015-09-11 Polipéptidos de il-22 y proteínas de fusión de il-22 fc y métodos de uso CR20150477A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361801144P 2013-03-15 2013-03-15
US201361800795P 2013-03-15 2013-03-15
US201361800148P 2013-03-15 2013-03-15
PCT/US2014/029652 WO2014145016A2 (en) 2013-03-15 2014-03-14 Il-22 polypeptides and il-22 fc fusion proteins and methods of use

Publications (1)

Publication Number Publication Date
CR20150477A true CR20150477A (es) 2015-10-26

Family

ID=54838123

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20150477A CR20150477A (es) 2013-03-15 2015-09-11 Polipéptidos de il-22 y proteínas de fusión de il-22 fc y métodos de uso

Country Status (2)

Country Link
US (1) US20180355009A1 (es)
CR (1) CR20150477A (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019165140A1 (en) * 2018-02-21 2019-08-29 Genentech, Inc. DOSING FOR TREATMENT WITH IL-22 Fc FUSION PROTEINS

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114206373A (zh) * 2019-07-26 2022-03-18 豪夫迈·罗氏有限公司 用于以IL-22 Fc融合蛋白预防或治疗移植物抗宿主病(GVHD)的给药
AU2020342512A1 (en) * 2019-09-03 2022-03-31 Amgen Inc. IL-22 oral, intra-rectal, or other gut-related compositions and methods of use thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019165140A1 (en) * 2018-02-21 2019-08-29 Genentech, Inc. DOSING FOR TREATMENT WITH IL-22 Fc FUSION PROTEINS

Also Published As

Publication number Publication date
US20180355009A1 (en) 2018-12-13

Similar Documents

Publication Publication Date Title
CL2015002654A1 (es) Polipéptidos de il-22 y proteínas de fusión de il-22 fc y métodos de uso
CL2024003234A1 (es) Polipéptidos modificados y usos de los mismos.
CO2018002450A2 (es) Proteínas de fusión de gitrl y usos de las mismas
AR107078A1 (es) Anticuerpo antimiostatina, polipéptidos que contienen regiones fc variantes así como métodos de uso
MX2023008559A (es) Proteínas de fusión fc heterodiméricas il15/il15ra.
CR20110544A (es) Anticuerpo antagonista específico para el heterodímero de alfa-4-beta-7
PT3445787T (pt) Composições e métodos para reprogramação de recetores de célula t com o uso de proteínas de fusão
MX2016000611A (es) Fusocinas que implican citocinas con una afinidad de union al receptor considerablemente menor.
CR20150618A (es) Anticuerpos receptores de antitransferina y métodos de uso
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
MX2017007247A (es) Receptor acoplado a la proteina g dirigida a anticuerpos y metodos de uso.
MX2016005631A (es) Anticuerpos anti-alfa-sinucleina y metodos de uso.
CR20170326A (es) Anticuerpos antimiostatina, polipéptidos que contienen regiones fc variantes, y métodos de uso
BR112016022841A2 (pt) cadeia j modificada
UY35407A (es) ?PROTEÍNAS DE FUSIÓN COMPRENDIENDO PORCIONES PDGF y VEGF DE UNIÓN Y MÉTODOS PARA SU USO?.
MX2018009524A (es) Composiciones del polipeptido de fusion tnfr: fc exentas de arginina y metodos de uso.
UY35835A (es) Anticuerpos específicos para FcRn.
MX2016009555A (es) Proteinas de union y metodos para utilizarlas.
MX2015017331A (es) Anticuerpos anti fc similar a receptor 5 (fcrh5).
CR20140212A (es) Anticuerpos anti-htra1 y métodos de uso
MX2016003530A (es) Proteina de fusion.
UY36678A (es) Anticuerpos anti-fcrn.
PE20151925A1 (es) Anticuerpos anti-igf-1r con abolicion de la union al fcrn y su utilizacion en el tratamiento de enfermedades oculares vasculares
DOP2016000105A (es) Anticuerpos anti-ccl17.
MX2015009155A (es) Uso de agonistas del receptor nicotinico de acetilcolina alfa 7.